

maribavir (LIVTENCITY)

Diagnoses Considered for Coverage:

- Treatment of cytomegalovirus (CMV) infection, post-transplant

Coverage Criteria:

For treatment of cytomegalovirus (CMV) infection:

- Patient is at least 12 years of age, **and**
- Patient received either a solid organ transplant or hematopoietic stem cell transplant (HSCT), **and**
- Disease is refractory to treatment with ganciclovir, valganciclovir, cidofovir or foscarnet, **and**
- Not being used with ganciclovir or valganciclovir, **and**
- Dose does not exceed 800 mg per day.

Coverage Duration: one year

Effective Date: 5/31/2023